This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jan 2;397(10268):4-5.

doi: 10.1016/S0140-6736(20)32624-6. Epub 2020 Dec 15.

Oral rimegepant for migraine prevention

Lars Edvinsson¹

Affiliations

PMID: 33338436
DOI: 10.1016/S0140-6736(20)32624-6

Comment

Oral rimegepant for migraine prevention

Lars Edvinsson. Lancet. 2021.

. 2021 Jan 2;397(10268):4-5.

doi: 10.1016/S0140-6736(20)32624-6. Epub 2020 Dec 15.

Author

Lars Edvinsson¹

Affiliation

¹ Department of Medicine, Lund University, 22100 Lund, Sweden. Electronic address: lars.edvinsson@med.lu.se.

PMID: 33338436
DOI: 10.1016/S0140-6736(20)32624-6

No abstract available

PubMed Disclaimer

Comment on

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Croop R, et al. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15. Lancet. 2021. PMID: 33338437 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information